Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.82 |
| ▸ | HPGD | P15428 | 5/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.82 |
| ▸ | MAPT | P10636 | 5/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.82 |
| ▸ | THRB | P10828 | 1/20 | 0.82 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3,7-Dimethoxyflavone SCHEMBL4278796 | 0.90 | ALDH1A1 (1.00) | KDM4ECYP3A4HPGDALDH1A1MAPT | |
| SCHEMBL4649960 | 0.90 | KDM4E (0.76) | KDM4ECYP3A4HPGDALDH1A1MAPT | |
| SCHEMBL14146407 | 0.89 | KDM4E (0.82) | KDM4ECYP3A4HPGDALDH1A1MAPT | |
| SCHEMBL5139273 | 0.85 | CYP3A4 (0.81) | KDM4ECYP3A4HPGDALDH1A1MAPT | |
| Fisetin Tetramethyl Ether SCHEMBL7116147 | 0.84 | ABCG2 (1.00) | KDM4ECYP3A4HPGDALDH1A1MAPT | |
| SCHEMBL7119192 | 0.84 | ABCG2 (0.81) | KDM4ECYP3A4HPGDALDH1A1MAPT | |
| SCHEMBL25197634 | 0.83 | CYP3A4 (0.72) | KDM4ECYP3A4HPGDALDH1A1MAPT | |
| SCHEMBL17786517 | 0.82 | MAPT (0.67) | KDM4ECYP3A4HPGDALDH1A1MAPT | |
| Bromide SCHEMBL11489117 | 0.81 | PLG (0.74) | KDM4ECYP3A4HPGDALDH1A1MAPT | |
| Demethoxykanugin SCHEMBL13582763 | 0.80 | CYP3A4 (0.78) | KDM4ECYP3A4HPGDALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-2247558-B1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2022-02-02 | — | — | EP | disclosed |
| EP-2247558-B1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2022-02-02 | — | — | EP | disclosed |
| EP-2599763-A1 | Novel imaging agents for detecting neurological dysfunction | Siemens Molecular Imaging, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-2599763-A1 | Novel imaging agents for detecting neurological dysfunction | Siemens Molecular Imaging, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-8318132-B2 | Imaging agents for detecting neurological dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318132-B2 | Imaging agents for detecting neurological dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318132-B2 | Imaging agents for detecting neurological dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTION USA, INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTION USA, INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTION USA, INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2247558-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | Siemens Medical Solutions USA, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009102498-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | FABP7, TSPO, SLC18A3 | KDM4E 4183/4885CYP3A4 1088/4885HPGD 1897/4885 |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | FABP7, SLC18A3, TSPO | KDM4E 4258/4885CYP3A4 1289/4885HPGD 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.